NYQ·Healthcare·$646M·#269 / 520 in Healthcare
DNA Ginkgo Bioworks Holdings, Inc.
42SPECULATIVE
CATEGORY BREAKDOWN
GROWTH0
QUALITY60
STABILITY33
VALUATION82
GOVERNANCE58
METRIC BREAKDOWN
Revenue Growth (YoY)
Year-over-year revenue growth rate
-25.1%
0
> 50% strong
Gross Margin
Revenue retained after direct costs
72.4%
100
> 50% strong
Cash Runway
Months of cash at current burn rate
12 months
39
> 24 months ideal
Debt / Equity
Total debt relative to shareholder equity
86.5%
22
< 25% strong
Price / Sales
Market cap relative to trailing revenue
3.8x
82
< 3x strong
Rule of 40
Growth rate plus operating margin
-204
0
> 40 excellent
Insider Ownership
Percentage of shares held by insiders
4.6%
37
> 20% strong
Share Dilution (12M)
Share count increase over last 12 months
-2.8%
100
< 5% ideal
SCORE HISTORY
RELATED STOCKS
COMPARE DNA WITH…
OR QUICK-COMPARE SECTOR PEERS
RELATED RESEARCH
4 Best Small-Cap Synthetic Biology Stocks — May 2026May 2, 2026SCORE ALERT
Get notified when DNA's score changes by 5+ points.
DATA INFO
Last updated: May 4, 2026
Sources: SEC EDGAR, Financial Modeling Prep, Yahoo Finance. Not financial advice.